A synthetic 15-amino-acid fragment related to a protective protein originally isolated from gastric juice.
Human clinical dosing for BPC-157 is not established. The ranges below summarize how amounts are described across the sourced, non-clinical protocols behind this compound, shown so you can recognize and sanity-check a number, not as guidance to follow. This is educational source context, not a protocol or recommendation.
Where sourced protocols commonly begin, to gauge individual response before any increase.
The most frequently reported day-to-day range in the protocols recorded for this compound.
Toward the top of what sourced protocols report. Higher is not established as more effective, and human safety data are limited.
These are drug amounts (mcg). The calculator converts that into syringe units or pen clicks from your vial strength and mixing volume; the dose and the unit count are not the same number.
A single subcutaneous dose per day is the most commonly reported cadence.
Larger daily amounts are sometimes divided into two smaller injections rather than one.
Reported use is usually organized in on/off blocks (for example ~4 weeks on, then a break) rather than continuously.
No randomized human trials establish a BPC-157 dose, schedule, or long-term safety profile; every number here comes from non-clinical models or unofficial protocols. As a contrast, some peptides do have trial-tested doses: retatrutide, for example, was studied at 4 mg once weekly in phase-2 research. BPC-157 has nothing equivalent.
Typically stored cold and dry, protected from light, per supplier certificate or CoA instructions.
Research practice usually refrigerates sterile solutions and avoids freeze-thaw cycles; follow validated lab SOPs.
Reconstitute gently; do not shake vigorously. Label concentration and date on the vial.
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 2 preclinical and 5 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Intra-articular knee injection, retrospective chart review16 adults aged 19-77 with knee pain of mixed causes at a Florida clinic | 4 mg (2 mL of a 2,000 mcg/mL solution); 2-4 mg when combined with TB4 | Single injection | Intra-articular | One procedure, with phone follow-up 6-12 months laterNot applicable | Alternative Therapies in Health and Medicine (PubMed)2021 |
| In this uncontrolled chart review, 11 of 12 patients given BPC-157 alone reported improvement and no adverse events were noted. There was no control group, no standardized outcome measure and most patients were surveyed by phone months after the injection, so the study cannot establish efficacy. | |||||
| Intravesical injection for interstitial cystitis, pilot study12 women aged 39-76 who had not responded to pentosan polysulfate | 10 mg total | Single procedure | Injections around the inflamed bladder wall during cystoscopy | One procedure, assessed at 6 weeksNot applicable | Alternative Therapies in Health and Medicine (PubMed)2024 |
| All 12 participants reported significant improvement on a global response questionnaire and no adverse events were recorded. The study was small, open-label and run at a private clinic with a compounded product, with no control arm. | |||||
| Intravenous infusion safety pilot2 healthy adults | 10 mg on day 1, then 20 mg on day 2 | One infusion per day for 2 days | Intravenous infusion in 250 mL saline over one hour | 2 days, with blood work on day 3Not applicable | Alternative Therapies in Health and Medicine (Europe PMC)2025 |
| Blood work and vital signs showed no measurable change in cardiac, liver, kidney, thyroid or glucose markers, and plasma levels returned to baseline within 24 hours. Two participants are far too few to establish safety, as the authors acknowledge. | |||||
| Phase 1 oral safety and pharmacokinetics trial (registered; results never posted)42 healthy volunteers aged 18-35 | Single 1, 3 or 6 mg (1 mg tablets), then 3 mg per dose | Single dose, then every 8 hours | Oral tablets (PCO-02) | 2 weeks of repeat dosingNone described | ClinicalTrials.gov2015 |
| PharmaCotherapia registered this placebo-controlled study in Tijuana for 2015-2016, but no results were ever posted and the record's status is listed as unknown. It remains the only formal dose-finding or safety trial ever registered for BPC-157 in humans. | |||||
| Preclinical2 rows | |||||
| Preclinical rodent tendon and muscle modelsRats with Achilles tendon transection, rotator cuff detachment and related injuries | 10 mcg/kg or 10 ng/kg (10 pg/kg also tested) | Once daily | Intraperitoneal injection in saline; intragastric and drinking-water dosing also used | Typically 14-21 days, through the end of the healing modelNone described | Pharmaceuticals (PubMed Central)2026 |
| A 2026 review of the tendon and muscle literature found that most in vivo studies used daily systemic injections at 10 mcg/kg or 10 ng/kg without any carrier or scaffold. All of this functional and biomechanical evidence comes from rats and from ex vivo tissue, not from human trials. | |||||
| Preclinical safety range summarized in a systematic reviewRat and dog toxicology studies | 6 mcg/kg to 20 mg/kg | Single and repeated doses | Intramuscular, intravenous, intraperitoneal and oral (animal models) | Up to 6 weeksNot applicable | HSS Journal (PubMed Central)2025 |
| Across the animal safety studies pooled in this 2025 review, no toxic or lethal dose was reached and no gross or microscopic organ changes were seen, but no study followed animals beyond 6 weeks. The review found no human safety data at all and reported a plasma half-life under 30 minutes. | |||||
| Community-reported5 rows | |||||
| Acute soft-tissue injury cycle | 250-500 mcg per day | Once or twice daily | Subcutaneous, as close to the injury as practical | 4-6 weeksPreventive cycles described as repeated every 3-4 months | Community resource2025 |
| A supplement retailer's 2025 guide lays out cycles by use case: 250-500 mcg a day for 4-6 weeks for acute injuries, 500-750 mcg a day split into two doses for 8-12 weeks after surgery, and 250 mcg a day as a preventive cycle. It frames daily consistency over several weeks as more important than the size of any one dose. | |||||
| Chronic tendon or joint cycle | 500 mcg | Twice daily | Subcutaneous near the affected joint; 500 mcg twice daily by mouth described for gut-focused use | 6-8 weeks minimumNot specified for this cycle | Community resource2025 |
| The same guide reserves the higher 1 mg per day total for long-standing tendon and joint complaints and lists oral capsules as the alternative when the target is the gut rather than a joint. These figures are the retailer's own practice summary, not trial data. | |||||
| Starter week, then a twice-daily course | 250 mcg to start; 250-500 mcg per injection thereafter | Once daily for 1-2 weeks, then twice daily (morning and evening) | Subcutaneous, near the injury or in the abdomen | 4-6 weeks (6-8 weeks at 500 mcg twice daily for demanding injuries)2-4 week break before any repeat | Community resource2026 |
| This 2026 protocol page describes three separate regimens rather than a titration: 250 mcg once daily as a common starting amount, 250-500 mcg twice daily for tissue recovery, and 500 mcg twice daily for 6-8 weeks for harder injuries. It states that there are no human dose-finding trials and that the figures come from animal studies and documented practice. | |||||
| Use-case dosing chart | 250 mcg (tendon, systemic) or 250-500 mcg (gut, post-surgical) | Once or twice daily | Subcutaneous near the injury or in the abdomen; oral capsules for gut-focused use | 4-6 weeks (tendon, systemic), 6-8 weeks (gut), 2-4 weeks (post-surgical)4-8 weeks on, 2-4 weeks off | Community resource2026 |
| An editorial site's 2026 chart separates a 250 mcg once-daily abdominal default from twice-daily tendon and gut protocols, and gives the reconstitution math (a 5 mg vial in 2 mL yields 250 mcg per 10 units on a U-100 syringe). It describes every protocol as practitioner-derived and not validated by human dose-ranging trials. | |||||
| Research-chemical dosing band | 250 mcg to start; 250-500 mcg common; 500 mcg upper | Once daily to start, then once or twice daily | Subcutaneous from a reconstituted vial | 4-6 weeks, sometimes 6-8 weeksNo evidence-based off period; stopping when the course ends described as the default | Community resource2026 |
| This 2026 guide quotes a wider 200-800 mcg per day community band and argues that the 4-hour half-life often repeated online has no published source, since rat and dog pharmacokinetics show elimination within minutes. It calls both the 6-8 week course and the 2-4 week break convention rather than evidence. | |||||
Community guides describe starting at 250 mcg once daily, injected subcutaneously near the injury or in the abdomen, to check tolerance before any increase. Early reports are of local comfort rather than measurable change, and many people report nothing at this stage.
The most-quoted band is 250-500 mcg once or twice daily at a consistent time each day, often split morning and evening. Community logs place reported mobility changes in weeks 3-6; there is no trial schedule to confirm or refute this.
Chronic tendon or joint protocols extend to 6-8 weeks at up to 500 mcg twice daily, and gut-focused oral protocols are also described at 6-8 weeks. Post-surgical protocols are shorter, at 2-4 weeks starting a day or two after the operation.
A 2-4 week off period is commonly described before any repeat course, with preventive cycles repeated every 3-4 months. One 2026 guide points out that no cycling rule is evidence-based because no adequate human trial exists.
Published human reports used single procedures (4 mg into a knee joint, 10 mg into the bladder wall) or a two-day intravenous pilot rather than multi-week courses, and the only registered trial planned two weeks of 3 mg by mouth every 8 hours. No human study has tested the daily subcutaneous course described above.
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide whose sequence was described by Predrag Sikiric's group at the University of Zagreb as a fragment of a protein found in human gastric juice. It has been studied almost entirely in rodent models of tendon, ligament, muscle, gut and vascular injury, where it is reported to speed healing. Human data are limited to three small pilot studies and one registered phase 1 safety trial that never posted results; it is not approved by any regulator, has been on the WADA prohibited list since 2022, and was placed in the FDA's Category 2 list of bulk substances that may present significant safety risks for compounding in 2023.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Animal and cell studies explore tendon, ligament, and muscle injury models, including Achilles-tendon transection and junction healing.
Early literature focuses on gut mucosal protection and experimental GI injury models, reflecting the peptide’s gastric origin story.
Preclinical work examines endothelial signaling (including VEGFR2 / nitric-oxide pathways) and collateral vessel responses after injury.
Rodent studies report changes in selected inflammatory and oxidative-stress markers; these are model-dependent findings, not clinical outcomes.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
A 2025 systematic review of English-language literature identified predominantly preclinical musculoskeletal studies plus very limited human reporting, and noted the absence of strong clinical safety datasets.
Rat Achilles-tendon and tendon-to-bone experiments report improved functional and structural healing markers versus controls in those models; results do not establish human efficacy.
Cell and explant studies describe effects on tendon fibroblast outgrowth, survival under oxidative stress, and migration-related signaling pathways.
Human evidence remains sparse (small pilot / retrospective reports). No large randomized controlled trials establish clinical benefit or a settled safety profile.
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Bepecin, PL-14736, PLD-116, PL-10, BPC 15, Gastric Juice Peptide Fragment, UNII 8ED8NXK95P, DrugBank DB11882
HEEWEZGQMLZMFE-RKGINYAYSA-N
Fragment related to gastric body-protection compound (BPC)
(4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid
6 curated references, each with its journal, year and study model, plus 4 community resources reported but not linked.